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Abstract 
Background: The health benefits of probiotics are well established and known to be strain-specific. 
However, the role of probiotics obtained from different origins and their efficacy largely remains 
unexplored. The aim of this study is to investigate the in vitro efficacy of probiotics from different 
origins.  
Methods: Probiotic strains utilized in this study include Lactobacillus acidophilus DDS-1 (human 
origin), Bifidobacterium animalis ssp. lactis UABla-12 (human origin), L. plantarum UALp-05 (plant 
origin) and Streptococcus thermophilus UASt-09 (dairy origin). Screening assays such as in vitro 
digestion simulation, adhesion, cell viability and cytokine release were used to evaluate the probiotic 
potential.  
Results: All strains showed good resistance in the digestion simulation process, especially DDS-1 
and UALp-05, which survived up to a range of 107 to 108 CFU/mL from an initial concentration of 109 
CFU/mL. Two human colonic mucus-secreting cells, HT-29 and LS174T, were used to assess the 
adhesion capacity, cytotoxicity/viability, and cytokine quantification. All strains exhibited good 
adhesion capacity. No significant cellular cytotoxicity or loss in cell viability was observed. DDS-1 
and UALp-05 significantly upregulated anti-inflammatory IL-10 and downregulated pro-inflammatory 
TNF-α cytokine production. All the strains were able to downregulate IL-8 cytokine levels.  
Conclusion: Of the 4 strains tested, DDS-1 demonstrated superior survival rates, good adhesion 
capacity and strong immunomodulatory effect under different experimental conditions. 
Key words: Probiotics, adhesion, gastrointestinal survival, immunomodulation  
Introduction 
Probiotic microorganisms are living, natural and 
safe modulators of gut microbiota. The term probiotic 
has been defined as “Live microorganisms that, when 
administered in adequate amounts, confer a health 
benefit on the host” [1]. Probiotics restore the 
beneficial composition of the gut microbiota by 
adhering to the intestinal epithelium, establishing 
microbial-host crosstalk and modulating immune 
responses [2]. Moreover, many strains produce 
regulatory metabolites, such as short chain fatty acids, 
which strengthen the intestinal epithelium in order to 
maintain a healthy state. Lactic acid bacteria (LAB) 
such as Lactobacillus, Bifidobacterium, Streptococcus, and 
Enterococcus species are widely used as probiotics, as 
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they were noted to have a clinical effect in reducing 
the symptoms of diarrhea, inflammatory bowel 
disease and irritable bowel syndrome [3,4,5]. To 
confer any health benefits, probiotics need to survive 
through the hostile environment of the digestion 
process in sufficient numbers (at least 106 colony 
forming units (CFU)), tolerating acids, bile, and 
pancreatic digestive enzymes, and finally adhere to 
the intestinal epithelium in the colon. Interestingly, 
most of the LAB probiotics have demonstrated high 
survival rates under simulated conditions of gastric 
juice and high bile salts concentrations [6, 7].  
Adherence of probiotics to the intestinal mucosal 
surfaces is also considered an essential probiotic trait 
as adhesion to colonic mucosa is the first step for gut 
colonization [6, 7]. The possible mechanism of 
adherence is via close interaction between surface 
adhesion proteins of bacteria and host cells [2, 6, 8]. 
Probiotics as generally considered safe as functional 
foods. A number of studies show that LAB strains are 
not toxic to intestinal epithelial cells [9, 10]. The safety 
of probiotics for human use has been the subject of a 
number of reviews by experts in food safety [11, 12, 
13]. These reviews support the safety and suitability 
of LAB for use as oral probiotics, a conclusion that is 
largely based on their long history of safe use in food 
and as dietary supplements.  
Experimental and human studies suggest that 
increased levels of pro-inflammatory cytokines TNF-α 
and IL-8 play a significant role in inducing intestinal 
inflammatory response [14]. LAB strains have been 
reported to reduce inflammation by downregulating 
IL-8 and TNF-α and by upregulating IL-10 levels [7, 
14, 15]. This immuno-modulatory effect of probiotic 
bacteria offers additional potential benefits for the 
prevention and management of gastrointestinal 
inflammation.  
Probiotic strain selection is often debated and 
linked to their origin. To date, many in vitro studies 
have reported the efficacies/functional properties of 
various probiotics obtained from different origins 
such as human, plant, dairy, and animal. However, 
most of these studies evaluated the efficacy of 
probiotic strain from a single origin strain, such as 
human [16, 17], dairy [15, 18], plant [19] or animal [6] 
to study their probiotic potential. To our knowledge, 
the current study is the first to compare probiotics of 
different origins. In our study, we investigated the 
efficacies of probiotics isolated from human, plant 
and dairy sources. To do this, the resistance and 
survival of these strains during the digestion process 
was assessed throughout buccal, stomach and 
intestinal conditions in a simulated in vitro setting. 
Subsequently, adhesion capacity and cytotoxicity 
studies were conducted on HT-29 and LS174T cells, 
and finally, the immunomodulation effect of these 
strains, particularly on IL-8, TNF-α and IL-10, was 
investigated on HT-29 cell supernatants. These 
findings would be of great importance to identify 
right probiotic strain for gut health. 
Materials and Methods 
Bacterial strains and origins 
Bacterial strains utilized in the study include 
Lactobacillus acidophilus DDS-1(human origin), 
Bifidobacterium animalis ssp. lactis UABla-12 (human 
origin), L. plantarum UALp-05 (plant origin) and 
Streptococcus thermophilus UASt-09 (dairy origin), and 
were obtained in freeze-dried, free-flowing 
lyophilized form from UAS labs, Madison, WI, USA. 
All the strains were routinely grown on De Man 
Rogosa agar supplemented with 0.05% (w/v) of 
L-cysteine (MRS-C) except UASt-09, which was 
grown on M17 agar supplemented with 10% (w/v) 
lactose, under anaerobic conditions at 37 0C for 48 h.  
Survival of strains in static in vitro digestion 
model  
A continuous, static in vitro digestion model was 
employed to assess the survival of selected strains as 
described by Versantvoort et al. [20]. The model 
includes a step-wise human digestive process, simul-
ating mouth, stomach, and intestinal compartments. 
However, it does not represent the continuous process 
of digestion. In order to mimic the continuous in vitro 
process of the human gastrointestinal tract, the 
present model was modified and adapted from 
Chavarri et al. [21] and Belguesmia et al. [17]. The 
chemical compositions of digestive fluids, enzymes, 
pH, temperature and residence time period in each 
compartment are reproduced in the modified model 
(Figure 1). Firstly, to reproduce the buccal conditions, 
1 mL of each bacterial strain comprising approxim-
ately 109 CFU were individually added to 9 mL of 
simulated saliva juice (pH adjusted to 6.8 ± 0.2) and 
incubated anaerobically at 37 0C for 5 min. After 
incubation, the suspension was centrifuged at 3000 
rpm for 5 min at 4 0C to recover the pellet containing 
each strain and to maintain the continuous process. 
The pellet was then re-suspended in 9 mL of 
simulated gastric juice comprised of 9 g/L of NaCl 
containing 0.3% (w/v) of porcine pepsin (Sigma 
Aldrich, St. Louis, MO, USA), and the pH adjusted to 
3.0 ± 0.2 and incubated anaerobically at 37 0C for 120 
min to mimic gastric conditions. After incubation, the 
gastric fluid was neutralized to pH 7.0 with phosph-
ate buffered saline to stop the pepsin digestion. The 
supernatants were discarded after centrifugation and 
intestinal digestion process was initiated. The 
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intestinal compartment included 0.3% (w/v) bovine 
bile (Sigma Aldrich, St. Louis, MO, USA) and 0.1% 
(w/v) pancreatic enzymes (MP Biomedical, CA, 
USA), pH was adjusted to 7.0 ± 0.2 before incubating 
anaerobically at 37 0C for 120 min. Overall, the 
bacterial strains were exposed to the various digestive 
conditions for a total of 240 min. After each step of the 
simulated digestion process, bacterial samples were 
collected and diluted in saline buffer. Lastly, 100 µL of 
each sample was plated on MRS-C/M17 agar plates 
and incubated at 37 0C for 24-72 h anaerobically to 
allow sufficient growth. The number of CFU/mL of 
each probiotic strain was calculated. 
Cell culture 
Human colonic epithelial cells (HT-29 and 
LS174T) were purchased from American Type Cell 
Culture (ATCC, Virginia, USA). For initial growth, 
HT-29 and LS174T were cultured in 75 cm2 tissue 
culture flasks and grown to confluence in complete 
medium  [McCoy and RPMI 1640 medium respect-
ively supplemented with 10% fetal bovine serum,  2 
mM L-glutamine and 100 U/mL of antibiotics 
(penicillin and streptomycin)]. At confluence, the 
adhered cells were washed with PBS, dissociated 
using 0.1 w/v TrypLE® Express (Gibco, Victoria, 
Australia) and re-suspended in 24-well cell culture 
plates at a density of approximately 5 x 104 cells/mL. 
Cells were incubated for 24 h and grown to 
confluency before exposing them to different treat-
ments for quantitative measurement of bacterial cell 
adhesion, cytotoxicity, and cytokine quantification. 
 Adhesion assay 
Each wells containing cells was washed thrice 
with serum-free culture medium before adding the 1 
mL of the bacterial suspension. Approximately 109 
CFU/mL of each bacterial strain was first suspended 
in the respective cell culture medium without serum 
and antibiotics. The cells containing bacterial 
suspensions were incubated for 4 h with 5% CO2. 
After 4 h incubation, cell monolayers were washed 
thrice with Hank’s balanced salt solution to remove 
the non-adherent bacteria in the wells. The cells were 
aspirated, lysed using 0.1% w/v TrypLE® Express for 
10-15 min and collected in saline solution. All cell 
lysates were serially diluted, plated on MRS-C/M17 
agar and incubated anaerobically for 48-72 h. The 
percentage of adhesion was calculated by the log of 
the number of adherent bacteria (log CFU) divided by 
the log of the total number of bacteria inoculated, 
multiplied by 100. Each determination was performed 
in triplicate. 
Cell cytotoxicity and viability 
Each bacterial suspension at approximately 109 
CFU/mL in respective serum-free cell culture 
medium was added to the cell monolayer in a 24-well 
plate and incubated for 8 h. After incubation, the 
supernatants were collected for determination of 
cytotoxicity using the lactate dehydrogenase (LDH) 
assay [22] and cell viability was assessed by standard 
trypan blue exclusion assay.  
The cellular cytotoxicity was assessed by the 
LDH in-vitro cytotoxicity assay (TOX7, Sigma- 
Aldrich, St. Louis, MO, USA). Briefly, the 
culture supernatants were centrifuged at 
250×g for 4 min. An aliquot containing 50 
µL of either blank (complete medium) or 
control (cells only) and cells treated with 
100 µL of each bacterial supernatants 
obtained after 8 h incubation, was mixed 
with 100 µL of a solution containing LDH 
assay mixture (LDH substrate, LDH dye, 
and LDH cofactor). The mixture was then 
incubated at room temperature for 20–30 
min and the reaction was quenched by the 
addition of 1N hydrochloric acid (15 μL). 
The absorbance was measured spectro-
photometrically using a plate reader 
(Spectra Max M2 microplate reader, 
Sunnyvale, CA, USA) at a wavelength of 
490 nm. The cellular viability was 
examined by Trypan Blue exclusion 
staining assay using a Countess 
Automated Cell Counter (Thermo-Fisher, 
Waltham, MA, USA). 
 
 
Figure 1. Graphical representation of chemical compositions, concentrations, digestive enzymes 
and pH used in in vitro simulated digestion process. (qs = quantity sufficient). 
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Quantification of cytokines 
HT-29 cells were used for quantification of IL-8, 
TNF-α, and IL-10 cytokine levels. The cells were 
subjected to probiotic/lipopolysaccharide (LPS) 
treatment under three different conditions, i.e., no-, 
co- and post- treatments, and LPS alone (control) in 
individual 24-well plates [23]. For no-treatment 
(probiotic only + HT-29 cells) conditions, 1 mL of each 
bacterial suspension (109 CFU/mL) was first added to 
each well containing cells and incubated at 37 0C, 5 % 
CO2 for 8 h. For co-treatment, each bacterial 
suspension was added to the cells and simultaneously 
challenged with LPS (100 ng/mL) (Sigma-Aldrich St. 
Louis, MO, USA) followed by incubation for 8 h. 
Lastly, in post-treatment, the cells were first 
challenged with LPS (100 ng/mL) and incubated for 4 
h, after which, each bacterial suspension (1 mL of 109 
CFU/mL) was added and re-incubated for 4 h. The 
supernatants from each well were collected and used 
for quantification of cytokines using Bio-Plex® Pro 
human cytokine assay kit (Bio-Rad®), according to the 
manufacturer’s protocol. Briefly, 50 µL of cytokine 
beads were added to the 96-well plate and incubated 
for 30 min before washing twice with wash buffer. 
Then 50 µL of each standard, blank and samples were 
added to the respective wells and incubated at room 
temperature on a shaker at 850 rpm for 30 min. After 
incubation, the wells were washed thrice and 25 µL of 
detection antibody was added to each well and 
incubated at room temperature on a shaker at 850 rpm 
for 30 min. 50 µL of streptavidin-PE was then added 
to each well and incubated at room temperature in a 
shaker at 850 rpm for 10 min. After three washes, 125 
μL assay buffer was added to each well and incubated 
at room temperature for 30 sec. After incubation, the 
plates were read on the Bio-Plex® 200 system and data 
was analyzed in Bio-Plex Data ProTM Software. All the 
experiments were performed in triplicates.  
Statistical analysis 
All the data are expressed as mean ± SEM 
calculated over three independent experiments with 
triplicates within each experiment. All the statistical 
analyses were performed using Graph Pad Prism 
software (version 6.0). The statistical differences 
between groups were measured using One-way 
ANOVA and Tukey’s multiple comparison tests for 
adhesion and cytotoxicity assays. Two-way ANOVA 
was used for digestion simulation and cytokine 
quantification.  
Results 
In vitro simulated digestion process 
All tested bacterial strains survived passage 
through the mouth compartment followed by the 
stomach and intestinal compartments during the 
simulated digestion process. The strains retained over 
75% of their initial concentration of 109 CFU/mL 
(Figure 2). DDS-1 exhibited the highest survival rates. 
No significant change in bacterial numbers of the 
strains was observed in the mouth compartment. 
During the transit from mouth to stomach, only 
UABla-12 (p < 0.001) and UASt-09 (p = 0.03) strains 
displayed a decrease of one logarithmic unit, which 
was significant when compared to DDS-1. In the 
intestinal compartment, DDS-1 and UALp-05 showed 
a decrease of one logarithmic unit, while UABla-12 
and UASt-09 further reduced by two logarithmic 
units. Overall, DDS-1 (p = 0.034), showed the highest 
resistance, followed by UALp-05 (p = 0.008), UASt-09 
(p = 0.002) and UABla-12 (p < 0.001) compared to 
initial concentration. The differences were statistically 
significant for UABla-12 (p < 0.001), UALp-05 (p = 
0.01) and UASt-09 (p < 0.001) when compared to 
DDS-1. 
Adhesion capacity  
The adhesion assay demonstrated the adherence 
capability of each probiotic strain to HT-29 and 
LS174T human colonic cells. All the strains were able 
to adhere efficiently to both colonic cell types. 
Although, DDS-1 and UALp-05 showed the highest 
adhesion capacity (87-93% and 89-92%, respectively) 
followed by UABla-12 and UASt-09 (79-86% and 
80-83%, respectively) for HT-29 cells (Figure 3A) the 
difference was not statistically significant. Compara-
tively, DDS-1 and UALp-05 showed relatively more 
adherence (81-88% and 80-87% respectively, Figure 
3B) to LS174T cells. The adhesion capacities for the 
strain UABla-12 (p = 0.02) was significantly lower than 
DDS-1 and UALp-05 (p = 0.03). 
 
 
Figure 2. Survival of each bacterial strain in the mouth, stomach and intestinal 
simulated in vitro digestion process. The samples were taken at each step and the 
number of CFU/ml was evaluated on agar medium. The date represents mean ± 
SEM of three replicates. Statistical analysis was by Two-way ANOVA. The 
values of groups designated with different letters are significantly different in the 
mouth and intestinal compartments (p < 0.05). For overall survival of individual 
strain *p < 0.01, **p < 0.005, ***p < 0.001 compared to DDS-1. 
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Cell cytotoxicity and viability 
To assess the safety of the tested strains and any 
cytotoxicity, LDH and trypan blue assays were 
performed on epithelial cell culture supernatants. 
After 8 h incubation, all the other strains except DDS-1 
showed a slightly increased LDH level, but, no 
significant cytotoxicity was observed. Similarly, after 
8 h incubation, DDS-1 showed no significant loss of 
cell viability but a slight loss of cell viability was 
observed with UABla-12, UASt-09, and UALp-05 
when compared to untreated cells. 
Immuno-modulatory effects by probiotic 
strains  
All strains modulated specific pro and anti- 
inflammatory cytokines (Figure 5). Each strain had a 
significant effect on the release of pro-inflammatory 
IL-8, and TNF-α as well as anti-inflammatory IL-10. 
When HT-29 cells were challenged with LPS for 8 h, 
this resulted in upregulation of IL-8 and TNF-α levels 
(1182.19 ± 165.78 and 2.56 ± 0.24 pg/mL, respectively). 
IL-8 secretion was significantly downregulated 
during no-treatment (Figure 5A) when compared to 
HT-29 cells alone as a control (574.24 ± 24.25 pg/mL). 
During co- (Figure 5B) and post-treatment (Figure 
5C), all the strains significantly downregulated IL-8 
levels (p < 0.0001) when compared to LPS control with 
the greatest effect shown by DDS-1 followed by 
UALp-05, UABla-12, and UASt-09.  Overall, there was 
a statistical by significant difference observed 
between DDS-1 and UASt-09 (p = 0.002) under no- 
and post-treatment, while there was no change in the 
IL-8 secretion between strains under co-treatment.  
Similar to the observed inhibition of release of 
IL-8, DDS-1 marked reduced TNF-α levels under the 
three tested conditions (Figures 5D-F). For no- 
treatment condition, TNF-α levels were downreg-
ulated by 1.22 ± 0.51 pg/mL by DDS-1 and 0.98 ± 0.49 
pg/mL by UALp-05 compared to the cells alone 
control (2.0 ± 0.32 pg/mL). Interestingly, UASt-09 
significantly upregulated the TNF-α levels (3.50 ± 0.50 
pg/mL, p = 0.002). Upon co-treatment, TNF-α levels 
were found to be downregulated to 1.0 ± 0.51 pg/mL 
by DDS-1, and (1.0 ± 0.26 pg/mL) by UALp-05, while 
no major change in TNF-α levels was observed with 
UABla-12 compared to LPS treated control (2.32 ± 0.51 
pg/mL). Relative to LPS treated control during the 
post-treatment, DDS-1 downregulated the TNF-α 
levels from 2.32 ± 0.51 pg/mL  to 0.68 ± 0.10 pg/mL  
followed by UALp-05 which reduced levels to 1.19 ± 
0.51 pg/mL. UABla-12 and UASt-09 did not affect the 
TNF-α levels. The differences were statistically 
significant between DDS-1 and UASt-09 (p = 0.002) 
under no-treatments and between DDS-1, UABl-12 (p 
= 0.01) and UASt-09 (p = 0.01) under post-treatment. 
All the strains, to some extent, upregulated the 
levels of anti-inflammatory cytokine IL-10 under 
no-treatment condition (as shown in Figure 5G). The 
basal levels of IL-10 on cells alone (control) were 2.72 
± 0.51 pg/mL and the strains upregulated by 25.25 ± 
1.99 pg/mL (DDS-1, p = 0.0003), 38.65 ± 6.40 pg/mL 
(UABla-12, p < 0.0001), 40.65 ± 3.75 pg/mL (UALp-05, 
p < 0.001) and 24.85 ± 8.12 pg/mL (UASt-09, p < 0.001). 
Upon co-treatment, DDS-1 significantly upregulated 
the levels of IL-10 by 45.53 ± 6.71, followed by 
UABla-12 (30.02 ± 4.26 pg/mL), UALp-05 (30.32 ± 6.21 
pg/mL) and UASt-09 (21.82 ± 5.6 pg/mL) (Figure 5H) 
compared to LPS treated control (3.45 ± 0.5 pg/mL). 
During post-treatment condition, only DDS-1 and 
UABla-12 were able to upregulate IL-10 levels by 76 
pg/mL and 62.84 pg/mL (p < 0.0001) respectively 
(Figure 5I). The statistically significant differences in 
IL-10 secretions were found between DDS-1 and 
UALp-05 (p < 0.001) under no-treatment and between 
DDS-1, UABla-12 (p < 0.001), UALp-05 (p < 0.001) and 
UASt-09 (p < 0.001) under co-treatment. There was no 
difference between strains under post-treatments. 
Discussion 
This study provides insightful 
information on the differences in the 
probiotic potential of individual LAB strains 
obtained from different origins.  
The role of the origin of probiotic strain 
selection is often debated. Theoretically, 
human gut colonization is facilitated by 
selecting probiotics of human origin. 
However, numerous studies have shown 
that maximum probiotic effect after human 
consumption is strain-specific but not 
restricted to human origin strains.  For 
example, B. animalis ssp. lactis of animal 
origin proved to be safe and modulated the 
gut microbiota in human subjects [24]. 
 
 
Figure 3. Adhesion capacity of each bacterial strain to HT-29 (A) & LS 174T cells (B) after 4 
h incubation period. Data represents mean ± SEM from three independent measurements. 
Statistical analysis was performed by One-way ANOVA with Tukey’s multiple comparison 
(pairwise) tests. *p < 0.01. 
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Similarly, B. lactis CNCM I‐2494 of dairy origin have 
alleviated minor digestive symptoms in healthy 
women [25]. Although there are numerous in vitro 
studies showcasing the functional properties of 
probiotics, there are no studies comparing probiotic 
efficacies with origins. To our knowledge, this the first 
study to elucidate the link between origin and efficacy 
of the probiotics in vitro with an assessment of the 
survival of each strain under simulated digestion 
process, their adhesion capacities to human colonic 
cells and their immunomodulatory effects. 
 Resistance to gastric and intestinal 
environments after oral administration is considered 
as one of the most important traits of probiotics. Many 
LAB strains have been reported to exhibit good 
resistance to pH around 2.5 ± 3.0 and 6.5 ± 0.5 in 
gastric and intestinal conditions respectively [7, 17, 26, 
27]. Generally, the L. acidophilus species is considered 
well adapted to survive harsh conditions of digestion. 
In fact, due to this ability, L. acidophilus has been 
considered an ideal vehicle for mucosal-targeted 
delivery of vaccines and biotherapeutics [28, 29]. In 
the present study, probiotic strains obtained from 
different origins were tested for their survivability in 
an in vitro simulated digestion static model and all of 
them displayed good survivability (106-108 CFU/mL) 
compared to their initial concentrations of 109 
CFU/mL. However, the concentrations of UABla-12 
and UASt-09 decreased around one logarithmic unit 
compared to their initial concentrations after exposure 
the strains to low pH and digestive enzyme in the 
gastric compartment. The viability loss of UABla-12 
may be linked to its obligate anaerobic nature, and for 
UASt-09 its acid tolerance capacity is strain-specific [6, 
7, 8, 15, 17, 36]. The acid/enzyme tolerance by 
lactobacilli (and most of the gram-positive strains) can 
be attributed, in part, to the presence of a constant 
gradient between extracellular and cytoplasmic pH 
[30, 31]. However, the strains in our study showed 
significantly better resistance in the gastric 
compartment compared to other studies [15, 17].  
In our study, the strains were not only exposed 
to different pH ranges, salivary, gastric and intestinal 
juices, but also to bile and digestive enzymes such as 
pepsin, and pancreatic enzymes in a continuous 
process. Overall, all the strains were decreased by 
only one logarithmic unit in the intestinal 
compartment. Specifically, DDS-1 maintained higher 
concentrations followed by UALp-05, UABla- 
12, and UASt-09. This phenomenon may be linked to 
the ability of these strains to produce 
bile salt hydrolase (BSH) and previous 
studies have demonstrated BSH genes 
in lactobacilli strains which are 
believed to be responsible for their 
resistance [32, 33, 34, 35].  
Adhesion capacity to colonic 
cells also plays a role in the selection 
of probiotic bacteria [17]. The human 
colonic cells such as HT-29, LS174T, 
and Caco2 are commonly used to test 
probiotic bacterial adhesion capacity 
[7, 15, 36]. High adhesion of LAB 
strains to colonic cells, as seen in our 
study, is reported in most studies [7, 
17, 15, 36]. Toscano and colleagues [7] 
tested 3 different strains of 
Bifidobacterium on HT-29 cells and 
found moderate to low adhesion 
capacity. The relatively low adhesion 
capacity of Bifidobacteria [7] was 
quite similar to that observed with 
UABla-12 strain in our study. The 
probiotic adhesion ability involves 
various biophysical and biochemical 
properties of probiotics and epithelial 
cells, includes electrostatic forces, 
hydrophobicity, steric & passive 
forces and specific cellular structures 
[15].  
 
 
Figure 4: Effect of probiotics on cellular cytotoxicity/viability of intestinal epithelial cells. Cell 
cytotoxicity and viability on HT 29 (A-B) and LS174T cells (C-D) was determined after 8 h incubation 
with each probiotic strain. Cell cytotoxicity was measured using LDH assay and data was represented as 
percentage LDH release. Viability was measured by trypan blue exclusion assay and data was 
represented as percentage viability. All the data is presented as mean ±SEM. Statistical analysis was 
performed by Two-way ANOVA test. * p < 0.05. 
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Figure 5. Detection of cytokines released in the supernatants of HT-29 cells (control) after three conditions using Bio-Plex® 200 system. Detection of IL-8 levels (A, 
B, C), TNF levels (D, E, F) and IL-10 levels (G, H, I) after no (probiotic only), co (LPS and probiotics together) and post-treatment (challenged with LPS first for 
4 h and later probiotics for another 4 h). The values of groups designated with different letters are significantly different (p < 0.05). Statistical analysis was done by 
Two-way ANOVA. * indicates the significant differences. *p <0.05, **p <0.005, ***p < 0.001, ****p < 0.0001. nd = not detected. 
 
Bu and colleagues [37] compared the differences 
in biochemical and cellular properties of LS174T and 
HT-29 cells, is a study extensively based on mucin 
expressions among the cells involving their role in 
adhesion. Mucus is mostly composed of mucins 
protein blocks which are encoded with MUC genes. 
Out of 20 identified human mucins, MUC 2 and MUC 
5 are implicated in various ligand-receptor 
interactions. Especially, MUC 2, a major gastro-
intestinal mucin secreted by goblet cells, plays a 
particularly important role in conferring the mucin 
barrier function of the gut. Morphologically, LS174T 
cells have many surface microvilli and more 
intercellular spaces than HT-29 cells. Surface 
microvilli play a role in the adhesion capacity of 
microbes to epithelial surfaces, and Bennett and 
colleagues [38] demonstrated that more surface 
microvilli establishes an electrostatic barrier which 
may repel the microbes from adhering to epithelial 
cells. High adhesion capacity of the strains used in the 
present study might be linked to the presence of MUC 
2 gene and/or comparatively less surface microvilli. 
Lactobacillus and Bifidobacterium species strains 
are generally considered to be safe [10, 17]. In the 
present study, none of the tested strains showed 
cytotoxic effects on HT-29 and LS174T cells. This is in 
agreement with the safety profile observed clinically 
with these strains [39, 40]. Furthermore, many studies 
have revealed the ability of various lactobacilli and 
bifidobacteria strains to limit the cytotoxicity caused 
by many entero-pathogens [41, 42]. In particular, the 
human origin strains, DDS-1 and UABla-12, have 
previously been shown to be safe and efficacious in 
multiple randomized controlled clinical studies. In a 
randomized controlled trial enrolling 96 preschool 
children with moderate-to-severe atopic dermatitis, 
subjects receiving DDS-1 and UABla-12 experienced a 
more rapid improvement in atopic dermatitis 
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questionnaire scores, as well as improved immune 
markers, when compared to placebo over an 8 week 
intervention period [39]. Similarly, in another 
randomized controlled trial involving 225 children, 
short-term use of DDS-1 and UABla-12 was found to 
significantly shorten the duration of acute respiratory 
tract infection, when compared to placebo [40]. 
Immunomodulatory capacity is considered as an 
additional factor for the selection of probiotics. A 
number of in vitro probiotic studies have investigated 
the anti-inflammatory properties of probiotics to 
modulate the release of pro- and anti-inflammatory 
cytokines including IL-6, IL-8, TNF-α and IL-10 [15, 
17, 43, 44]. In our study, most of the tested strains 
downregulated the pro-inflammatory IL-8, and 
TNF-α and upregulated IL-10 levels when compared 
to controls, but the rate and extent of immunomodu-
latory effect varied between the strains and under 
different conditions. The upregulation of pro- 
inflammatory cytokines upon LPS treatment could be 
attributed to T cell proliferation and activation, and 
the upregulation of anti-inflammatory cytokines in 
presence of these strains could be associated with 
counteracting molecular mechanisms leading to T cell 
activation [23]. As shown in previous studies, 
probiotics could influence the activation of dendritic 
cells (DCs) and macrophages of the innate immune 
system [3, 45]. Upon activation, DCs release 
anti-inflammatory TGF-β and IL-10, which allows the 
proliferation of adaptive T cells.  
All the tested strains significantly suppressed 
IL-8 levels under no-, co- and post-treatment 
conditions. NF-ĸB and IκB pathways are crucial 
targets in the initiation of inflammatory responses 
evoked by cytokines including IL-6, IL-8, and 
pathogens. Ohkusa and colleagues [44] showed that 
VSL#3 probiotic suppressed IL-8 levels by inhibiting 
nuclear translocation of NF-ĸB. Reduction of IL-8 
levels in our study could be attributed to inhibition of 
NF-ĸB. Only DDS-1 and UALp-05 were able to 
downregulate TNF-α levels in all conditions, which is 
in agreement with previous probiotic studies [15, 23]. 
Both UABla-12 and UASt-09 having no stimulatory 
effect on TNF levels under co- and post-treatment was 
consistent with the previous studies which actually 
showed an increase in TNF-α levels with probiotic 
treatment [15, 43]. The mechanism of downregulation 
of TNF-α levels by LAB strains has been linked to 
activation of certain pathways like extracellular- 
signal-regulated kinase (ERK), p38 and phosphoin-
ositide 3-kinase (PI3K) pathways [46]. The beneficial 
effects of probiotics can be immuno-stimulatory 
rather than immuno-suppressive, suggesting that 
probiotics can restore the breach of the innate immune 
system and prevent the onset of inflammation by 
stimulation of TNF-α [2, 3]. All the tested strains 
induced the release of anti-inflammatory cytokine 
IL-10 during no- and co-treatment itself. However, 
only DDS-1 and UABla-12 were able to induce the 
secretion of IL-10 levels during post-treatment, which 
is consistent with previous studies conducted in 
colonic cells [23, 46]. In this particular case, a few 
studies reported that release of IL-10 by probiotics is a 
strain, origin, and dose-dependent [15, 43, 47]. 
Overall, all the strains demonstrated strong 
immunomodulatory effects; but specifically, the strain 
DDS-1, which strengthens its probiotic potential.  
Taken together, all the strains showed good 
survival in the simulated digestion process, strongly 
adhered to intestinal epithelium and demonstrated an 
adequate immunomodulatory effect. However, the 
comparative analysis of the data suggests that origin 
may affect their probiotic potential. This was 
particularly in the case of human origin DDS-1 strain, 
which showed superior characteristics compared to 
other strains and could be an interesting candidate for 
more intensive research to elucidate and harness the 
bioactive effects.  
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